Skip to content
Dodge was part of the NHS England board and executive leadership team from 2014 to 2022, leading the organisation’s approach to reforms and restructuring, as well as its ‘innovation and transformation work’.
Before this, Dodge was director of the NHS Group and head of policy for the Department of Health. Additionally, in 2005 and 2006 he was the Prime Minister’s senior adviser on the NHS.
WITH HEALTH SYSTEMS UNDER INCREDIBLE PRESSURE, HANOVER IS WELL EQUIPPED TO HELP COMPANIES UNDERSTAND HOW THEIR PRODUCTS AND SERVICES CAN ADD REAL VALUE. IAN WILL GIVE OUR CLIENTS EVEN DEEPER INSIGHT AND EXPERTISE.
Dodge now joins a suite of Hanover senior advisers focused on market access and health system innovation, alongside former payers, regulators, industry execs and health system managers. Here, he will support clients to understand the NHS environment and any changes to its structure, practices, technologies and therapies.
Andrew Harrison, group managing director of health at Hanover, said: “This is an era of breakthrough science with new therapies and technologies that can save lives and transform health systems. With health systems under incredible pressure, Hanover is well equipped to help companies understand how their products and services can add real value. Ian will give our clients even deeper insight and expertise.”
Other recent additions to the team include Malcolm Qualie, former medicines lead for specialised services at NHS England, and former NICE highly specialised technology lead Josie Godfrey.
Dodge said: “Bringing new therapies and technologies to the NHS is about finding a win-win that delivers better outcomes for patients and value for taxpayers. I look forward to helping clients identify opportunities to improve healthcare in the UK and internationally.”
Hanover Health is part of the Hanover Group, and provides in-market and international campaigns and advisory programmes across product and corporate communications, policy, public affairs and market access.